Sugi Predict

Sugi Predict / Compounds / SCHEMBL2175049

SCHEMBL2175049

SCHEMBL2175049

CC(C)(C)c1ccc(N2CCN(C(=O)[C@H]3CN(C(=O)O)C(C4CCCC(C(=O)NO)C4)[C@@H]3O)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ ADAM10 O14672 14/20 0.43
▸ ERBB2 P04626 14/20 0.43
▸ MMP2 P08253 14/20 0.43
▸ MMP9 P14780 7/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CNR2 P34972 3/20 0.37
▸ MMP3 P08254 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175055 0.78 ADAM10 (0.48) ADAM10ERBB2MMP2MMP9ALDH1A1
SCHEMBL3457772 0.74 ADAM10 (0.54) ADAM10ERBB2MMP2MMP9ALDH1A1
SCHEMBL2174696 0.73 ADAM10 (0.55) ADAM10ERBB2MMP2MMP9ALDH1A1
SCHEMBL2173437 0.73 ADAM10 (0.55) ADAM10ERBB2MMP2MMP9ALDH1A1
SCHEMBL5622789 0.73 ADAM10 (0.48) ADAM10ERBB2MMP2MMP9MAPT
SCHEMBL3458102 0.69 ADAM10 (0.55) ADAM10ERBB2MMP2MMP9ALDH1A1
SCHEMBL27651741 0.68 ALDH1A1 (0.46) ADAM10ERBB2MMP2MMP9MEN1
SCHEMBL2173803 0.67 ADAM10 (0.59) ADAM10ERBB2MMP2MMP9MMP3
SCHEMBL5648063 0.67 ADAM10 (0.60) ADAM10ERBB2MMP2MMP9MMP3
SCHEMBL2176292 0.67 ADAM10 (0.60) ADAM10ERBB2MMP2MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US claimed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US claimed
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 ADAM10 25/4885ERBB2 2986/4885MMP2 4/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.